Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.63 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940702 | 0.97 | CYP3A4 (0.65) | CYP3A4TNKSCYP2D6GRM2CACNA1G | |
| SCHEMBL9940498 | 0.90 | CYP3A4 (0.60) | CYP3A4TNKSCYP2D6GRM2 | |
| SCHEMBL9941174 | 0.90 | CYP3A4 (0.60) | CYP3A4TNKSCYP2D6 | |
| SCHEMBL9978089 | 0.88 | CYP3A4 (0.60) | CYP3A4TNKSCYP2D6 | |
| SCHEMBL9978085 | 0.87 | CYP3A4 (0.59) | CYP3A4TNKSCYP2D6 | |
| SCHEMBL9978031 | 0.86 | CYP3A4 (0.57) | CYP3A4TNKSCYP2D6 | |
| SCHEMBL9940766 | 0.84 | CYP3A4 (0.58) | CYP3A4TNKSCYP2D6CACNA1GCACNA1H | |
| SCHEMBL9978059 | 0.81 | CYP3A4 (0.51) | CYP3A4TNKSCYP2D6 | |
| SCHEMBL18053801 | 0.80 | CYP3A4 (0.56) | CYP3A4TNKSCYP2D6CACNA1GCACNA1H | |
| SCHEMBL15019760 | 0.79 | CYP3A4 (0.82) | CYP3A4TNKSCYP2D6CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| EP-2651933-B1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R & D IRELAND (IE) | 2013-10-03 | — | — | US | disclosed |
| WO-2012080449-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, ZC3HAV1, ZC3HAV1L | CYP3A4 167/4885TNKS 2569/4885CYP2D6 700/4885 |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | CYP3A4 149/4885TNKS 2375/4885CYP2D6 639/4885 |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | CYP3A4 149/4885TNKS 2375/4885CYP2D6 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.